Titel
Accueil
Navigation principale
Contenu
Recherche
Aide
Fonte
Standard
Gras
Identifiant
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Accueil
Plus de données
Partenaires
Aide
Mentions légales
D
F
E
La recherche est en cours.
Interrompre la recherche
Recherche de projets
Projet actuel
Projets récents
Graphiques
Identifiant
Titel
Titel
Unité de recherche
PCRD EU
Numéro de projet
03.0600-2
Titre du projet
INTACT: Identification of novel targets for cancer therapy
Titre du projet anglais
INTACT: Identification of novel targets for cancer therapy
Données de base
Textes
Participants
Titel
Textes relatifs à ce projet
Allemand
Français
Italien
Anglais
Mots-clé
-
-
-
Autre Numéro de projet
-
-
-
Programme de recherche
-
-
-
Description succincte
-
-
-
Autres indications
-
-
-
Résumé des résultats (Abstract)
-
-
-
Références bases de données
-
-
-
Textes saisis
Catégorie
Texte
Mots-clé
(Anglais)
Anticancer therapy; functional biology; genetics
Autre Numéro de projet
(Anglais)
EU project number: 506803
Programme de recherche
(Anglais)
EU-programme: 6. Frame Research Programme - 1.1.2b
Description succincte
(Anglais)
See abstract
Autres indications
(Anglais)
Full name of research-institution/enterprise:
Institut suisse de recherche expérimentale sur le cancer ISREC
Résumé des résultats (Abstract)
(Anglais)
Despite intensive worldwide research efforts, cancer remains a devastating, often poorly treatable disease. We propose to develop and apply new functional genomics technologies that will provide unique approaches to the design of new pathway- specific cancer therapies. Our specific objectives are:
1) To develop large-scale functional genomic analysis to identify novel mechanisms involved in cancer development; specifically, we will generate the tools and technologies to carry out genome-wide loss-of-function screens in mammalian cells.
2) To apply these technologies to specific models of major human cancer-causing pathways to define novel targets for therapy.
3) To use existing and generate novel mouse models and non-invasive tumour imaging to validate and assay cancer gene function in vivo and to develop new treatment modalities.
4) To develop cell-based assays for cancer-relevant genes and pathways that will serve as readout for the identification of anticancer agents through the screening of chemical compound libraries.
5) To distribute and disseminate the novel technologies for the study of gene function in vitro and vivo within the consortium and to researchers in the European Community.
To reach these objectives we have formed a multidisciplinary research consortium, including top scientists with extensive experience in developing innovative genomics technologies and with an excellent track-record in identifying key signalling molecules involved in cancer, as well as SMEs with experience in identifying cancer-relevant genes and in screening chemical compound libraries. The location of most of the partners at leading European cancer centres will ensure optimal conditions for the development of novel cancer-specific treatments. This proposal provides new possibilities of 'Translating basic knowledge of functional oncogenomics into cancer diagnosis and treatment' in compliance with the main goal in the 'LifeSciHealth' call in the sixth framework programme.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 03.0600-2
SEFRI
- Einsteinstrasse 2 - 3003 Berne -
Mentions légales